Parkinson's disease: An Overview of Management

Sawthi Garnepudi

Garnepudi Sawthi Priyadarshini Institute of pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur -522017, Andhra Pradesh, India.

Abstract

Parkinson's disease is classified as a neurodegenerative condition, with the death of dopamine-producing neurons thought to be the cause. PD is now far more common than it was a decade ago. The majority of pharmaceutical treatments for Parkinson's disease (PD) target alpha-synuclein by upregulating cerebrosidase, blocking LRRK2, and lowering its elimination through immunotherapy. The most common neurodegenerative illness is Parkinson's disease, followed by Alzheimer's disease. In most cases, Parkinson's disease first manifests between the ages of 55 and 65. It affects 1 to 2 percent of people over 60, and in 3 to 5 percent of cases, it advances to the ages of 85 and 89. Motor symptoms, which include bradykinesia, tremors, rigidity, and dystonia, are uncontrollable movements brought on by severe forms of Parkinson's disease. Non-motor symptoms like hysteria, sadness, constipation, and sleeplessness are also brought on by Parkinson's disease. Science and engineering principles are combined in nano biosensors to identify Parkinson's illness. Nanotechnology can also pass the blood-brain barrier with drugs in the form of nanoparticles. However, the usage of nano biosensors in biological systems is limited due to their new nature. By altering cellular chemical profiles and potentially upsetting cell metabolism and homeostasis, nano biosensors pose a threat to the ability to discern between basic biological processes and sensor-induced aberrations.

Keywords: Parkinson's disease, Neurodegenerative disease, alpha-synuclein, Lewy bodies, pharmacological treatment, herbal treatment, therapeutic targets diagnostics

References

1. Abais JM, Xia M, Zhang Y, Boini KM, Li PL. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector?. Antioxidants & redox signaling. 2015 May 1;22(13):1111-29. https://doi.org/10.1089/ars.2014.5994.
2. Aghili Z, Nasirizadeh N, Divsalar A, Shoeibi S, Yaghmaei P. A highly sensitive miR-195 nanobiosensor for early detection of Parkinson’s disease. Artificial cells, nanomedicine, and biotechnology. 2018 Oct 31;46(sup1):32-40.
3. Curtis WM, Seeds WA, Mattson MP, Bradshaw PC. NADPH and mitochondrial quality control as targets for a circadian-based fasting and exercise therapy for the treatment of Parkinson’s disease. Cells. 2022 Aug 4;11(15):2416.
https://doi.org/10.3390/cells11152416
4. Curtis WM, Seeds WA, Mattson MP, Bradshaw PC. NADPH and mitochondrial quality control as targets for a circadian-based fasting and exercise therapy for the treatment of Parkinson’s disease. Cells. 2022 Aug 4;11(15):2416.
https://doi.org/10.3390/cells11152416
5. Fruncillo S, Su X, Liu H, Wong LS. Lithographic processes for the scalable fabrication of micro-and nanostructures for biochips and biosensors. ACS sensors. 2021 Apr 8;6(6):2002-24.
6. Ivanidze J, Skafida M, Pandya S, Patel D, Osborne JR, Raj A, Gupta A, Henchcliffe C, Dyke JP. Molecular imaging of striatal dopaminergic neuronal loss and the neurovascular unit in Parkinson disease. Frontiers in Neuroscience. 2020 Sep 18;14:528809.
7. Parnham J, MacMahon D. Diagnosis and management of Parkinson’s disease: what the NICE guidelines say, and why. Primary health care. 2008 Apr 1;18(3).
8. Dey B, Hwisa NT, Khalf AM, Mitra A, Katakam P, Rao CB. Pharmaco-epidemiological Studies on Self Medication and Drug Utilization Pattern in Chronic Diseases via Prescription Auditing. International Journal of Scientific Research in Knowledge. 2013 Nov 1;1(11):464.
9. Banigo AT, Azeez TO, Ejeta KO, Lateef A, Ajuogu E. Nanobiosensors: applications in biomedical technology. InIOP Conference Series: Materials Science and Engineering 2020 Mar 1 (Vol. 805, No. 1, p. 012028). IOP Publishing.
10. Bollella P, Gorton L, Antiochia R. Direct electron transfer of dehydrogenases for development of 3rd generation biosensors and enzymatic fuel cells. Sensors. 2018 Apr 24;18(5):1319.
11. Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson’s disease in 2012: relevant clinical aspects. Parkinson’s disease. 2012;2012(1):198316.
https://doi.org/10.1155/2012/198316.
12. Adam H, Gopinath SC, Arshad MM, Parmin NA, Hashim U. Distinguishing normal and aggregated alpha-synuclein interaction on gold nanorod incorporated zinc oxide nanocomposite by electrochemical technique. International journal of biological macromolecules. 2021 Feb 28;171:217-24.
13. Cheng L, Hao X, Liu G, Zhang W, Cui J, Zhang G, Yang Y, Wang R. A flexible pressure sensor based on silicon nanomembrane. Biosensors. 2023 Jan 12;13(1):131.
14. Kolapudi RK, Kapudasi J, Koppula SB, Chandu B. Stem Cells Treatment for the Future Heart Diseases. Drug Invention Today. 2012 Jun 1;4(6).
15. Ravella S, Angel M, Subramanian H, Thangavel N, Namballa M, Lokesh D, Mishra AK, Nagaraju GV. Navigating the Future of Cancer Diagnosis: A Comprehensive Review of Novel Approaches for Community-Based Treatment. future.;1:6.
https://doi.org/10.3390/s22197581.
16. Kim JH, Suh YJ, Park D, Yim H, Kim H, Kim HJ, Yoon DS, Hwang KS. Technological advances in electrochemical biosensors for the detection of disease biomarkers. Biomedical Engineering Letters. 2021 Nov;11(4):309-34.
17. Ivanidze J, Skafida M, Pandya S, Patel D, Osborne JR, Raj A, Gupta A, Henchcliffe C, Dyke JP. Molecular imaging of striatal dopaminergic neuronal loss and the neurovascular unit in Parkinson disease. Frontiers in Neuroscience. 2020 Sep 18; 14:528809.
18. Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry. 2020 Aug 1;91(8):795-808.
19. Amulya A, Sirisha V, Rao CB, Chennam JV. CURRENT TRENDS ON ROLE OF NANO PARTICLES ON PULMONARY DISEASES. International Journal of Research in Pharmacy and Chemistry. 2012;2(3):685-703.